Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190684 · ClinicalTrials.gov registry record · Phase 3
Long-Term, Open Label Atomoxetine Study
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,553
- Enrollment target
NCT00190684 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,553 participants.
The verdict
NCT00190684, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,553 participants
- Enrollment target
Study Summary
To learn about the safety and any side effects of atomoxetine when given to children and adolescents for about 5 years (long-term) and to learn whether atomoxetine can help children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who take the drug for about 5 years (long-term). Study participants can be atomoxetine naive, atomoxetine experienced whose therapy has been interrupted or, atomoxetine experienced on a known stable dose.
Interventions
- DRUG atomoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,553 participants |
| Start Date | 2000-08 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00190684
The ClinicalTrials.gov registry entry for NCT00190684 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,553 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which atomoxetine is the first listed.
NCT00190684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00190684 about?
NCT00190684 is a clinical study titled "Long-Term, Open Label Atomoxetine Study". To learn about the safety and any side effects of atomoxetine when given to children and adolescents for about 5 years (long-term) and to learn whether atomoxetine can help children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who take the drug for about 5 years (long-term). ...
What is the current status of trial NCT00190684?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,553 participants. The study started on 2000-08. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00190684?
The interventions under investigation include: atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00190684?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.